New combo vaccine aims to shield seniors from RSV and HMPV

NCT ID NCT06556147

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times

Summary

This early-stage study tests a new vaccine (VXB-241) designed to protect against two respiratory viruses: RSV and HMPV. About 144 healthy adults, including those aged 60-83, will receive one dose of the vaccine at different strengths to check its safety and how well it boosts the immune system. Some participants will get a booster shot about a year later to see if revaccination is beneficial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

University of the Sunshine Coast

Morayfield, Queensland, 4506, Australia
University of the Sunshine Coast

Sippy Downs, Queensland, 4556, Australia
University of the Sunshine Coast

South Brisbane, Queensland, 4101, Australia
Veritus Research

Bayswater, Victoria, 3153, Australia

Conditions

Explore the condition pages connected to this study.

HEALTHY VOLUNTEERS HEALTHY VOLUNTEERS